Best Practices For Adaptive Trial Designs Continue To Evolve
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data Monitoring Committees are one option to look at interim data and implement pre-planned adaptations to clinical trials, but the new duty could conflict with DMC’s safety responsibility, participants at a DIA conference note.
You may also be interested in...
Can Basket Trials Boost Use Of Bayesian Statistics?
Basket trials like NCI-MATCH could show the value of adaptive clinical trial designs based on advanced Bayesian statistics, furthering a goal of the 21st Century Cures draft legislation.
Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.
Sponsors’ Use Of Adaptive Designs Appears To Be Growing
A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.